Journal of Molecular Neuroscience

, Volume 20, Issue 3, pp 357–362

Calpain inhibitors, a treatment for alzheimer’s disease

Position paper

Authors

  • Fortunato Battaglia
    • Department of Psychiatry, Nathan Kline Institute for Psychiatric ResearchNYU School of Medicine
  • Fabrizio Trinchese
    • Department of Psychiatry, Nathan Kline Institute for Psychiatric ResearchNYU School of Medicine
  • Shumin Liu
    • Department of Psychiatry, Nathan Kline Institute for Psychiatric ResearchNYU School of Medicine
  • Sean Walter
    • Department of Psychiatry, Nathan Kline Institute for Psychiatric ResearchNYU School of Medicine
  • Ralph A. Nixon
    • Department of Psychiatry, Nathan Kline Institute for Psychiatric ResearchNYU School of Medicine
    • Department of Psychiatry, Nathan Kline Institute for Psychiatric ResearchNYU School of Medicine
Alzheimer’s Therapeutics: Cognitive Enhancement

DOI: 10.1385/JMN:20:3:357

Cite this article as:
Battaglia, F., Trinchese, F., Liu, S. et al. J Mol Neurosci (2003) 20: 357. doi:10.1385/JMN:20:3:357

Abstract

Calpains modulate processes that govern the function and metabolism of proteins key to the pathogenesis of Alzheimer’s disease, including tau and amyloid precursor protein. Because activation of the calpain system might contribute to the impairment of synaptic transmission in Alzheimer’s disease, we are currently testing the hypotheses that a treatment with calpain inhibitors might restore normal cognition and synaptic transmission in a transgenic model of Alzheimer’s disease, the APP (K670N:M671L)/PS1(M146L) mouse. Findings derived from these studies will provide a novel approach to cognitive enhancement in Alzheimer’s disease.

Index Entries

Alzheimer’s diseasecalpaintransgenic modelshippocampusamyloid precursor proteinpresenilin 1

Copyright information

© Humana Press Inc 2003